Genentech: Eric Stefanich | Senior Director & Distinguished Scientist, Translational Pharmacokinetics and Pharmacodynamics (tPKPD), Development Sciences

Scientists / Our Scientists

"The path to longevity at Genentech involves having a strong mentor/role model, trusted network of colleagues, and exciting opportunities."

Years at Genentech

Publications at Genentech

I am a Senior Director and Distinguished Scientist in tPKPD where I lead a group of scientists accountable for the translational PKPD strategy of large molecule therapeutics in the OMNI portfolio from LI in Research through first in human clinical trials. I have been a key representative and/or leader on cross-functional project teams and have made significant scientific contributions to the company portfolio.

Over the years, I have accumulated extensive experience in strategic planning and implementing IND associated activities and have a strong track record of regulatory submission and interaction with health authorities. All together I have expertise in translational pharmacology, drug development, Immunology, and leading cross functional teams.

Featured Publication

Sialic Acid Mediated Endothelial and Hepatic Uptake: a Mechanism based Mathematic Model Elucidating the Complex Pharmacokinetics and Pharmacodynamics of Efmarodocokin Alfa, a Variably Glycosylated Fusion Protein.

J Pharm Sci. 2024

X. Tao, S. Sukumaran, G. Sperinde, C. Liu, M. I. Beardsley, P. Day, M. Kalo, E. Ayewoh, H. Cai, Y. Wang, I. Jun, K. Hirst, V. Nguyen, S. Chung, D. Lee, A. Lekkerkerker, E. Stefanich.

View Abstract

I am a group leader for large molecule translational PKPD in the OMNI disease areas. I am also the therapeutic area lead for Immunology, Regenerative medicine, and Metabolic disease. In these roles I am accountable for the translational PKPD strategy for large molecule therapeutics in the OMNI portfolio from LI in Research through first in human clinical trials.

I am a member of our department leadership team, and a member of the Development Sciences extended leadership team. I am also a reviewer for the Development Sciences Review Forum.

I co-lead a Development Sciences and Translational Medicine Cell therapy group that leads the development strategy for cell therapy and interfaces with other organizations involved in the research and development of cell therapies in gRED.

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy

Frontiers in Pharmacology,

Rajbharan Yadav; Suzanne Schubbert; Patrick Holder; Eugene Y. Chiang; Nargess Kiabi; Liz Bogaert; Irene Leung; Rumana Rashid; Kendra N. Avery; Christine Bonzon; John Desjarlais; Shomyseh Sanjabi; Amy Sharma; Lepherd; Amy Shelton; Pamela Chan; Yanqiu Liu; Louis R. Joslyn; Iraj Hosseini; Stefanich; Amrita Kamath; Matthew Bernett; Vittal Shivva

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Eric Stefanich

Senior Director & Distinguished Scientist, Translational Pharmacokinetics and Pharmacodynamics (tPKPD), Development Sciences

Featured Publication

Sialic Acid Mediated Endothelial and Hepatic Uptake: a Mechanism based Mathematic Model Elucidating the Complex Pharmacokinetics and Pharmacodynamics of Efmarodocokin Alfa, a Variably Glycosylated Fusion Protein.